Wednesday, July 18, 2012

OMG, LCOI! Open Source Pharma: Creative Commons Coming To Pharma

I had an interesting phone conversation yesterday with Jerry Matczak, Community Manager, Lilly Clinical Open Innovation, Eli Lilly and Company. Yes, "Open" and "Innovation" together in the same phrase from a pharmaceutical company - OMG! LCOI is the acronym for Lilly Clinical Open Innovation, a venture that Lilly hopes "can transform clinical research and development." How will they achieve this? "We look to engage in the open for insight, innovation, talent and wisdom to drive new capabilities to fight disease and meet patient needs." There it is again, "open" and "innovation" in the same sentence.

The devil is in the details and I hope to interview Mr. Matczak soon on my Pharma Marketing Talk show.

It's was a happy coincidence that my conversation with Matczak followed yesterday's show about "Pharma Wikipedians: The Pros and Cons of Pharma Employees Editing Wikipedia Articles" (use the playback widget below to listen to that podcast).


Listen to internet radio with Pharmaguy on Blog Talk Radio

An even happier "coincidence" was an audio commentary from my friend Brad Pendergraph (@bradatpharma), former Senior Manager, Consumer Digital and Social Engagement at Novartis, in response to a question raised during my show.

Brad posted his commentary to Audioboo, which is "a simple way of recording audio while on the move and adding as much useful data to it as possible, such as photos, tags and location." Audioboo is the audio equivalent of Twitter -- you can record as many 3-minute audio messages from your smartphone as you like. I signed up immediately so that I can post Auioboo comments while on the road at drug industry conferences.

In his audio commentary, Brad touched upon how pharma deals with proprietary information. "Is pharma really going to let some of its information 'go general'?," Brad asked. He mentioned "creative commons" and "taking a look at what material you [pharma] have and figuring out how you can distribute it to people in the social media space in ways that they can understand and work with that are still compliant." Brad was suggesting pharma use creative commons rather than the more restrictive copyright when distributing information. Listen to his comments using this Audioboo playback widget:



Meanwhile, back at LCOI, here's their take on "open Innovation" published on the LCOI website (here):
There’s plenty of evidence that drug development is broken. The estimated efficacy rate of drugs for many common illnesses comes in at 50% or below, and a recent Forbes article by Matt Herper suggests the cost of bringing a new drug to patients is twice the already-big-number commonly used – over $4 billion per drug.

Patients need better.

The Lilly Clinical Open Innovation team exists to make it better. We believe that Open Innovation models – focused on clinical drug development – can result in transformational gains in value-to-patients and efficiency.

We also believe that open data, linked, crowdsourced, consumed and curated by experts outside (as well as inside) the walls of pharma will bring innovative insights and wisdom. And that open communities will set and meet objectives to reduce costs and improve outcomes.

We’ll explore challenge driven innovation and gamification to tap into expertise which might otherwise be missed. We embrace open source development to maximize technical contribution and benefit, and will Work Out Loud to assure transparency on our projects. To manage rights in a distributed digital age we leverage Creative Commons licensing. In the open, with no strings attached.
That’s a lot of buzzwords, and even more to actually try to do. Too much for the smallish Lilly COI group for sure – but that’s kind of the point. Open Innovation promises that we can all play bigger than we are, and enables greater innovation than any individual or organization can accomplish on it’s own.
Keep tuned for an announcement of an upcoming show where I will interview Jerry and Brad about "Open Source Pharma."

Monday, July 16, 2012

"The Crowd is My Only Drug," Says GSK Olympics Anti-Doping DTC Ad Campaign

GlaxoSmithKline (GSK) will raise awareness of its role in anti-doping measures at the London 2012 Olympic Games as part of its first consumer-facing corporate campaign in the UK (see here).

Advertisements will appear across a range of media, including television, and outdoor advertising space, commencing July 23. One TV ad is currently available on Youtube:



Obviously, when the athlete star of this video is quoted as saying "The Crowd is My Only Drug," he means illegal drugs that some athletes may use to boost performance, not the drugs sold be GSK for legitimate use. But I wonder if social media "crowds" -- as in "Wisdom of the Crowd" -- can replace some Rx drugs for some people? I'm thinking about GSK drugs such as diet pill Alli and diabetes drug Avandia, both of which have been problems for GSK (see here and here).

JNJ Attempts YouTube Humor to Promote a DTC Advertising Goal

The goal of every direct-to-consumer (DTC) ad is to get people to visit their doctors and ask about the advertised Rx drug. But are these ads effective?

The drug industry often defends DTC ads, claiming they ARE effective in achieving this goal. Some studies, however, seem to indicate that once people visit their physicians, they do not ask for the advertised drug (read, for example, "Advertisers Don't Know How DTC Works. Say wha?").

But the ads may not even be effective in driving people to see their physicians. Maybe that's why Johnson and Johnson (JNJ) recently promoted a YouTube video it uploaded more that two years ago called "The Appointment." It's an non-branded attempt to use humor. JNJ's corporate Twitter account (@JNJComm) recently posted this tweet:

"Afraid to visit the doctor? Don't be! Watch 'The Appointment' for medicinal laughter - and important info > http://t.co/0PQanPNF @JNJVideo"

On the YouTube page, JNJ introduces the video: "Many people are wary of making a doctors visit. In The Appointment, some extreme humor works to make several important points about why you should visit your doctor and most importantly things you should not be afraid to understand and ask. Enjoy and no, there really isnt a needle that big!"

Here's the video:




A few people do not think the video is funny. One commenter (yes, JNJ accepts comments on its YouTube channel) said:
"I'm not one to start a YouTube spitting contest - I'm just saying that this seems to be a bit (not massively!) insensitive to both the clinicians and the patients who are trying to treat each other better. Your ultimate message in the vid is perfect - it just strikes me as missing the mark in its opening approach."
One commenter even said it was "misguided":
"Wow. I'm sure you meant it to be funny, but I have to say, this is the worst-conceived pitch I've ever seen for being an empowered patient. In addition to the patient looking like something of a simpleton, to me it charicatures doctors in the worst possible way too.. I'm sure y'all meant well, but wow, this is misguided."
To which JNJ replied:
"I understand and respect your point of view. It was supposed to be a lighthearted reminder to those who might not be practicing preventive care. You are already an informed, empowered patient who has dealt with, and become educated about, a life threatening disease. Although it uses caricutures of doctors and patients, the video is aimed at those who might have misconceptions or fears about visiting their doctors for annual check ups and other routine care."
What do you think?

Sunday, July 15, 2012

EU's EMA Plans to Open Up Proprietary Drug Trial Data to Outside Investigators

European Medicines Agency (EMA) -- the European drug regulator -- "is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information," according to Reuters news (here).

This is big news depending on how EMA makes these large data sets available to outside investigators and which investigators are granted access. Reuters reports that the agency will host a conference in November to determine who has access to what and how fast. As I always said of the FDA, if an agency wants to delay something, its best bet is to hold a meeting to discuss it or sponsor research to study it.

The drug industry has long argued that the clinical data it presents to the FDA and other regulators as part of the drug approval process is proprietary -- ie, closely guarded trade secrets. But critics contend that important safety data about drugs is hidden from outside investigators and the data is critical for maintaining public health.

"It will make a huge difference to public health," said Peter Gotzsche, director of the nonprofit Nordic Cochrane Centre in Denmark, which carries out systematic healthcare reviews. "The pharmaceutical industry routinely exaggerates the benefits of its drugs and plays down the harms or hides them. By getting access to material held by drug regulators we may discover that many drugs are less effective than we thought they were and also more harmful."

In 2011, Gotzsche wrote paper titled "Why we need easy access to all data from all clinical trials and how to accomplish it." In it, he said "Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests" (find the full text here: "Call for Easy Access to ALL Clinical Trial Data").

A case in point is Vioxx, whose harmful side effects once were secrets known only to Merck and the FDA.

"Europe used to be behind the FDA in terms of openness and transparency but now Europe is ahead," Gotzsche said. Will the FDA ever follow EMA's lead?

I doubt it. FDA has been very gun shy of the pharmaceutical industry, which pays over 60% of the agency's budget for approving drugs. Also, the drug industry has no qualms about taking the FDA to court to defend itself. Usually, the FDA is sued by pharma for limiting the industry's First Amendment right to free and open speech. In this case, however, the industry would argue that FDA has no right itself to "speak" freely about clinical data provided to it by drug companies.

UPDATE (7/16/2012): While the EU plans to provide access to "confidential" clinical trial data, the FDA is prohibited by LAW to do so. The Wall Street Journal reports that the FDA is monitoring some of its own employees who are suspected of leaking confidential medical device data to the press (read about this here).

Saturday, July 14, 2012

“We do things at Pfizer that are best for shareholders of Pfizer." You Gotta Problem with That?

I can't believe a Pfizer "spokesperson" (Corporate Secretary and Chief Governance Counsel, Matthew Lepore) said:

“We do things at Pfizer that are best for shareholders of Pfizer" 

when defending Pfizer's continued financial support of Heartland Institute, an organization whose president Joe Bast claimed that the public health community has a campaign to "demonize smokers" based on "junk science" (find the story here: "Pfizer Refuses To Pull Funding From Anti-Science Front Group").

Among the books authored by Joe Bast is "Please Don’t Poop in My Salad (and other essays opposing the war against smoking)" (see his 2008 resume here).

First of all, it's shameful for a drug company that on one hand promotes campaigns to help people quit smoking (eg, CHANTIX direct-to-consumer commercials) while on the other hand supports an organization that believes anti-smoking campaigns are based on "junk science." How does that resonate with people who are taking CHANTIX?

Secondly, doesn't Mr. Lepore know that Pfizer's trademarked slogan is "Working Together for a Healthier World" and NOT "Working Together for a Profitable Investor"?

Lepore also stated that Pfizer "isn’t concerned" by the decisions of Eli Lilly, GlaxoSmithKline, and Bayer, to disassociate themselves with Heartland. "We can't be very knee jerk on every issue that is brought to our attention," said Marc Scarduffa, Vice President, Government Relations & Public Affairs.

Which reminds me of a typical New Yorker conversation ender: "You gotta problem with that?"

Gamification's Brave New World Circa 1984: Operation Frog

There's a lot of brouhaha these days in pharma circles about "gamification" as if it were the newest thing since sliced bread. What is "gamification," you ask? According to the Gamification.org wiki (here):
"Gamification typically involves applying game design thinking to non-game applications to make them more fun and engaging. Gamification has been called one of the most important trends in technology by several industry experts. Gamification can potentially be applied to any industry and almost anything to create fun and engaging experiences, converting users into players."
You might find this "Gaming Goes Mainstream" infographic interesting.

An example of an attempt to apply gamification to the pharmaceutical industry is the "Syrum" Facebook game being developed by Boehringer Ingelheim. The release of that game, however, has been delayed for nearly a year (see "Pharma & Fun, Not Oxymoronic? Here Comes Gamification!" and "'A Drug is Developed:' Easier than Launching an Educational Facebook Game about Drug Development?").

I know from first-hand experience how difficult it is to develop educational games. I started my career -- such as it is -- back in 1984 designing an educational life science personal computer-based game. It was a simulation of a frog dissection. The objective was to use the keyboard or joystick to move a simulated hand, pick up simulated instruments, and "dissect" a simulated frog and identify its organs. At the end, the user (usually a high school biology student) was challenged to reverse the process by putting the frog back together (the game aspect). If successful, the user was rewarded with a fun animation of the (simulated) frog dancing off in a top hat and cane -- no harm done (except to the frog I dissected doing research for the simulation). The codename was "Defrogger" but it was published by Scholastic as "Operation: Frog".

Operation: Frog ran on the Apple II computer, which at the time had the most advanced graphics of any personal computer on the market. It was an 8-bit computer with a screen resolution of 280x196. You could get 16 colors using a technique called "dithering." Here's a screen shot showing the frog's digestive system:


You can count the pixels without a magnifying glass! To get this level of detail from an 8-bit 16-color computer display was quite a challenge requiring planning and storyboards (I also created the graphics and wrote the screen text and user's manual). Here's the storyboard for the dissection screen, which is evidence that I actually did this more than 28 years ago (OMG!):


In my proposal to Scholastic I said that "dissection of a living animal or one stewed in formaldehyde is an unpleasant experience for many biology students and teachers alike. Not only does it require the sacrifice of many animals, it is also expensive and potentially dangerous. Consequently, many children never carry out a dissection."

Okay, I was playing it up a bit too much. However, the program was a hit. It was  featured in the October 15, 1984 issue of Newsweek Magazine and played a role in a 1987 California court case in which Jenifer Graham, a brave 15-year-old high school girl, defended her right to refuse to dissect a frog. Ms. Graham suggested "she could learn just as much from models or computer graphics as her fellow students learn from the dissection of a frog. It seems incredible," said a Los Angeles reporter at the time (here), "that a school would resort to a dead frog, formaldehyde, forceps and scalpels in this age of computer graphics."

At the time, Ms. Graham was vilified. Unfortunately, although we've come a long way in terms of computer graphics and gaming, students who refuse to dissect real frogs are still vilified (see, for example, "Middle school student claims teacher bullied her over refusing to dissect frog").

For more Operation: Frog screen shots, see my Pinterest Gamification Board.

Friday, July 13, 2012

Can Pharma Cure Alzheimer's Disease? A Pfizer Pre-Launch Multichannel Marketing Case Study

Last month I quipped on this blog that "Pfizer's Social Media Initiatives are Getting Old." Actually, that was a review of Pfizer's new "Get Old" initiative, which Pfizer says is a "first-of-its-kind online community" where people can "get and share information, add to the dialogue and contribute to the growing body of knowledge about this important topic."

In that post, I suggested that Pfizer's real goal was to court advocacy groups such as the Alzheimer’s Association in advance of the announcement of results from an Alzheimer clinical trial of its drug ddsigned to treat the disease.

Just a couple of days ago, on the CBS Evening News, I saw an interview of Rae Lyn Burke, "An Alzheimer's researcher who is also a patient." Ms. Burke is participating in a clinical trial of bapineuzumab (bap-ih-NOOZ-uh-mab), a drug with a funny, Irani-sounding name. Turns out that bapineuzumab is a Pfizer/Johnson and Johnson drug.

Ms. Burke's participation in an Alzheimer clinical trial is old news. According to an August, 2011, San Francisco Chronicle story (here), "Burke worked on some of the initial research into bapineuzumab" (her LinkedIn profile indicates that she is "senior Director at SRI International," a CRO that is likely running the Pfizer Alzheimer clinical trial).

The 2011 story also revealed that "Burke has been in the trial for almost two years, and should find out shortly whether she's been receiving the active drug or a placebo. If she's on the placebo, she intends to switch to the active drug as soon as possible.

She obviously was in the bapineuzumab arm of the study, or switched, because in her recent CBS interview she said that she taking the drug and it was "slowing the decline, but I don't think it's making me better." That's too bad.

Is this all part of Pfizer's multichannel marketing of bapineuzumab prior to its approval by the FDA (if indeed it ever does get approval)?

It's no coincidence that Burke's story was resurrected shortly before results from key studies of two Alzheimer's drugs -- including bapineuzumab -- are to be released. But the journalism stinks: the CBS Evening News story is practically the same, word-for-word as the 2011 San Francisco Chronicle piece cited above. Maybe CBS owns the San Francisco Chronicle or maybe it's becoming more like a blog rather than a primary source of news.

There are also stories in newspapers about these trials, such as this one from the Mercury News: "Alzheimer's drugs could be pharmaceutical industry's last-gasp efforts to cure disease" and this one from the Denver post: "Alzheimer's cure may lie in three drug (sic) tested over past decade." Both of these stories are based on the same AP story, which does NOT mention "cure" but says the drugs are meant to "slow the course of Alzheimer's disease."

I always find it odd that reporters often overstate the efficacy of drugs, sometimes in collusion with drug companies (see, for, example, "BI Masters the Art of WOM through Its 'Parrots,' er, Spokespersons"). Perhaps the local news reporters were influenced to use the word "cure" by Pfizer, JNJ, Lilly, and/or Baxter PR parrot trainers?

As I mentioned in my "Get Old" post, institutional investors doubt that treatments for Alzheimer's disease being developed by Pfizer (and Lilly) will "achieve the main goals of their ongoing late-stage trials." Those goals certainly are NOT to CURE Alzheimer's, but only "aim to clear the sticky plaque gumming up patients' brains."

"Everybody in the field is probably holding their breath that there is something positive to come out of these trials," said Dr. Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center. "It may not be a home run" in terms of improving memory and cognition, but if brain imaging or spinal fluid tests show the drugs are hitting their target, "they will be regarded as successes," he said.

Next week, at the 4th Annual Social Communications & Healthcare: Case Studies and Roundtables confernce in NYC, I hope to discuss this with Pfizer's Andrew Topen (VP of Global Media Relations and Digital Communications), Caroline Roan (VP of Corporate Responsibility and Reputation), and/or  Bob Libbey (Senior Director of Global Colleague Communications). These exceutives led the GetOld.com site project and will present the Get Old Case study ("Pfizer Starts a Conversation about Aging") at the conference.

NOTE: Pharma Marketing News is aMedia Partner for this conference. You can get a $20 discount off registration if you have the secret word, which you can find here.